Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard

Executive Summary

Howard Liang comes from an investment background with years of experience honed as the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the Chinese biotech prepared for its initial public offering on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.

Advertisement

Related Content

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)
Celgene Eyes IO Growth With BeiGene China Pact
FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel